Lymphoma & CLL Subtypes

Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was delighted to...

FDA grants CLR 131 fast track designation for the treatment of patients with lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia

On May 26, 2020, CLR 131, a radiotherapeutic phospholipid drug...

KEYNOTE-204: Pembrolizumab versus brentuximab vedotin R/R classic Hodgkin lymphoma

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was pleased to speak to John...

Nivolumab plus AVD as first-line treatment for high-risk classic Hodgkin lymphoma

Paul J. Bröckelmann and colleagues conducted the open-label, multicenter, randomized, phase II NIVAHL study...

Positive interim results announced for TRPH-222 in patients with NHL

On May 18, 2020, positive interim results were announced from the multi-center, open-label, phase I study of TRPH-222...

(177)Lu lilotomab satetraxetan receives positive opinion for orphan drug designation from EMA for MZL

On May 14, 2020, (177)Lu lilotomab satetraxetan received a positive opinion from the European...

Brentuximab vedotin plus CHP is approved by the European Commission and China for the treatment of adult patients with sALCL

On May 14, 2020, brentuximab vedotin in combination with cyclophosphamide,...

Phase III study of omidubicel in patients with high-risk hematologic malignancies meets primary endpoint

Positive results from a phase III study of omidubicel, a cell therapy product of expanded...